lundi 24 juillet 2017

Onco Actu du 24 juillet 2017

2.5 Etiologie - Gènes

Lesser-known gene mutations may boost breast cancer risk in Jewish women [Reuters]

3.7 Alcool

Heavy drinking will kill 63,000 people over next five years, doctors warn [The Guardian]

4.2 Dép., diag. & prono. - Génome

What I learned from home DNA testing [The Guardian]

5.12 Immunothérapies

Cancer patients' grey hair unexpectedly darkens in drug study [The Guardian]

5.12.2 Immunothérapies - CAR-T

A Rush to Develop ‘Utterly Transformative’ Gene Therapies Against Cancer [NY Times]

5.12.3 Immunothérapies-combinaisons

COX-2 Inhibitors May Reverse IDO1-mediated Immunosuppression in Some Cancers [AACR]

5.12.6 Immunothérapies - AMM

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval [Reuters]

5.2 Pharma

Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma [Bayer]

Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug [EndPoints]

Bayer says asbestos-related tumor treatment misses key goal [Reuters]

5.2.3 Pharma - économie

In internal memo, AstraZeneca chief Soriot reassures staffers as Teva rumors swirl [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

EMA Backs Eight New Medicines, Turns Down Drugs From Nektar & Vanda [RAPS]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017 [EMA]

Refusal of the marketing authorisation for Onzeald (etirinotecan pegol) [EMA]

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall [EndPoints]

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma [Roche]

Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) [Novartis]

CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer [Roche]

Bavencio [EMA]

Roche's Tecentriq receives positive opinion from EU medicines agency [Reuters]

EU medicines agency recommends approval of Novartis leukaemia drug Rydapt [Reuters]

Europe backs nuclear medicine for cancer that killed Steve Jobs [Reuters]

6. Lutte contre les cancers

HIV and cancer teams double up to seek out new disease killers [Reuters]

6.10.1 Politiques (USA)

Medical research funding: Why we must keep our foot on the accelerator [The Cancer Letter]

6.3 Associations/Fondations

Klausner: CRUK Grand Challenge—more than just another grant [The Cancer Letter]

Cancer Research UK awarding £20 million Grand Challenge grants to cancer researchers worldwide [The Cancer Letter]

6.9 Controverses

French funding agency president resigns amidst tensions [Science]